This study highlights the aggressive nature of AITL and identifies several readily accessible laboratory parameters as important prognostic factors. The protective effect of PD-1 positivity on survival outcomes warrants further investigation. While CHOP/CHOPE remains the standard treatment, the addition of novel targeted therapies shows promise for improving patient outcomes in this challenging lymphoma subtype.
Wang et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: